Cargando…

Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb

The European Commission mandated EFSA to issue a statement concerning confirmatory data that were not submitted by the set deadline by the applicant following Article 12 reviews under Regulation (EC) No 396/2005 for the following substances/commodity combination: 2,4‐d on buckwheat and other pseudo‐...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546792/
https://www.ncbi.nlm.nih.gov/pubmed/34729094
http://dx.doi.org/10.2903/j.efsa.2021.6910
_version_ 1784590260014940160
collection PubMed
description The European Commission mandated EFSA to issue a statement concerning confirmatory data that were not submitted by the set deadline by the applicant following Article 12 reviews under Regulation (EC) No 396/2005 for the following substances/commodity combination: 2,4‐d on buckwheat and other pseudo‐cereals, fenhexamid on kiwis, iprovalicarb on lettuces, escaroles/broad‐leaved endives and roman rocket/rucola. EFSA prepared a statement containing a final conclusion on the completeness of the data necessary to support the existing tentative maximum residue levels (MRLs) and indications to risk managers whether or not the tentative MRLs currently established by Regulation (EC) No 396/2005 could be maintained. The statement was circulated to Member States for consultation via a written procedure before finalisation.
format Online
Article
Text
id pubmed-8546792
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85467922021-11-01 Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb EFSA J Statement The European Commission mandated EFSA to issue a statement concerning confirmatory data that were not submitted by the set deadline by the applicant following Article 12 reviews under Regulation (EC) No 396/2005 for the following substances/commodity combination: 2,4‐d on buckwheat and other pseudo‐cereals, fenhexamid on kiwis, iprovalicarb on lettuces, escaroles/broad‐leaved endives and roman rocket/rucola. EFSA prepared a statement containing a final conclusion on the completeness of the data necessary to support the existing tentative maximum residue levels (MRLs) and indications to risk managers whether or not the tentative MRLs currently established by Regulation (EC) No 396/2005 could be maintained. The statement was circulated to Member States for consultation via a written procedure before finalisation. John Wiley and Sons Inc. 2021-10-26 /pmc/articles/PMC8546792/ /pubmed/34729094 http://dx.doi.org/10.2903/j.efsa.2021.6910 Text en © 2021 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority. https://creativecommons.org/licenses/by-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nd/4.0/ (https://creativecommons.org/licenses/by-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.
spellingShingle Statement
Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb
title Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb
title_full Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb
title_fullStr Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb
title_full_unstemmed Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb
title_short Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb
title_sort lack of confirmatory data following article 12 mrl reviews for 2,4‐d, fenhexamid and iprovalicarb
topic Statement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546792/
https://www.ncbi.nlm.nih.gov/pubmed/34729094
http://dx.doi.org/10.2903/j.efsa.2021.6910
work_keys_str_mv AT lackofconfirmatorydatafollowingarticle12mrlreviewsfor24dfenhexamidandiprovalicarb